Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
Authors:
Open Access
- 2 February 2010
- Vol. 116 (S4) , 1053-1058
Abstract
BACKGROUND: Significant antitumor effects were previously observed with radioimmunotherapy (RIT) using an anti‐carcinoembryonic antigen (CEA) monoclonal antibody (F6) labeled with iodine‐131 in medullary thyroid cancer (MTC)‐bearing nude mice. Nevertheless, no complete response was achieved. Because angiogenesis is critical for tumor growth, bevacizumab is used to treat solid tumor in clinical practice. The present pilot study evaluated toxicity and efficacy of RIT combined with bevacizumab in mice subcutaneously grafted with TT MTC cells.METHODS: Groups of 4‐6 nude mice were treated with 5 μg/g bevacizumab twice weekly during 4 weeks and/or 100 MBq of 131I‐F6. For combined therapy, bevacizumab was given at Day 0 followed by 131I‐F6 at Day 30. The control group received no treatment. Animal weight, hematological toxicity, tumor volume, and serum calcitonin were monitored for 2 or 4 months.RESULTS: Bevacizumab alone induced no cytopenia and no significant weight loss. A weight loss of 12 ± 1% and 15 ± 2% was observed in mice treated by RIT alone or bevacizumab + RIT, respectively. RIT alone and combined treatment induced leukopenia and anemia. RIT alone and RIT plus bevacizumab induced tumor responses with minimum relative tumor volume of 0.38 ± 0.24 and 0.15 ± 0.07%, respectively, and time to progression of 35 ± 5 and 56 ± 11 days, respectively.CONCLUSIONS: Pretreatment with bevacizumab improved RIT efficacy, with similar toxicity as compared as RIT alone. Cancer 2010;116(4 suppl):1053–8. © 2010 American Cancer Society.Keywords
This publication has 20 references indexed in Scilit:
- Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor GroupJournal of Clinical Oncology, 2006
- Antibody Pretargeting Advances Cancer Radioimmunodetection and RadioimmunotherapyJournal of Clinical Oncology, 2006
- Editorial: Radioimmunotherapy, a New Breakthrough in the Treatment of Follicular Non-Hodgkin's Lymphoma: The European PerspectiveCancer Biotherapy and Radiopharmaceuticals, 2006
- Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphateBlood, 2005
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationCancer Cell, 2004
- Tumor Response to Radiotherapy Regulated by Endothelial Cell ApoptosisScience, 2003
- Pretargeting with the Affinity Enhancement System for RadioimmunotherapyCancer Biotherapy and Radiopharmaceuticals, 1999
- Angiogenesis as a Predictor of Long-term Survival for Patients With Node-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 1996
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971